Clinical Trials
245 trialsPersonalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
M.D. Anderson Cancer Center
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Evaluation of the Pathobiology of CALR-mutated MPN Cells
Wake Forest University Health Sciences
Therapeutic RSK1 Targeting in Myelofibrosis
Washington University School of Medicine
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
St. Jude Children's Research Hospital
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
Case Comprehensive Cancer Center
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
City of Hope Medical Center
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
M.D. Anderson Cancer Center
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Fred Hutchinson Cancer Center
First-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Malignant Pleural Effusion
China-Japan Friendship Hospital
Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm
Université Catholique de Louvain
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Memorial Sloan Kettering Cancer Center
Haplo-Cord HSCT for AML/MDS
Fujian Medical University Union Hospital
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
City of Hope Medical Center
AML-MDS 001
University of Virginia
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Dana-Farber Cancer Institute
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Icahn School of Medicine at Mount Sinai
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
PedAL BCU, LLC
MoTD
University of Birmingham
EWOG MDS 2006
University Hospital Freiburg
PACRIMYEL
Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas
MPN Childhood Registry
University of Erlangen-Nürnberg Medical School
PB-KIT in SM
The First Affiliated Hospital of Soochow University
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
MITHRIDATE
University of Birmingham
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
CER
Cancer Support Community, Research and Training Institute, Philadelphia
DATAMAST
Imagine Institute
MYELO-CAN:TXA
University of Manitoba
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
M.D. Anderson Cancer Center
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
CYTOK-AZA
Nantes University Hospital
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Masonic Cancer Center, University of Minnesota
UHKT-PTC-TMI-1
Institute of Hematology and Blood Transfusion, Czech Republic
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
M.D. Anderson Cancer Center
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Wake Forest University Health Sciences
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic